Molecular Basis for Drug Resistance in HIV-1 Protease
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the inhibitors bind are well characterized. From thi...
Main Authors: | Celia A. Schiffer, Kelly Thayer, Ellen A. Nalivaika, Ayşegül Özen, Moses M. Prabu-Jeyabalan, Madhavi N.L. Nalam, Nancy M. King, Rajintha M. Bandaranayake, Jennifer F. Murzycki, Seema Mittal, Madhavi Kolli, Yufeng Cai, Akbar Ali |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2010-11-01
|
Series: | Viruses |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4915/2/11/2509/ |
Similar Items
-
Comparative Studies on Retroviral Proteases: Substrate Specificity
by: József Tözsér
Published: (2010-01-01) -
Insights into the Role of Tick Salivary Protease Inhibitors during Ectoparasite–Host Crosstalk
by: Mohamed Amine Jmel, et al.
Published: (2021-01-01) -
HIV-1 Gag Non-Cleavage Site PI Resistance Mutations Stabilize Protease/Gag Substrate Complexes In Silico via a Substrate-Clamp
by: Gary S. Laco
Published: (2021-11-01) -
Editorial: Proteases of the prokaryotic cell envelope
by: Rosana E. De Castro, et al.
Published: (2022-08-01) -
Cellular functions of the ClpP protease impacting bacterial virulence
by: Mazen E. Aljghami, et al.
Published: (2022-12-01)